Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape. Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 4 and 1 respectively for Proliferative Diabetic Retinopathy (PDR). Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Proliferative Diabetic Retinopathy (PDR) Overview 6 Therapeutics Development 7 Pipeline Products for Proliferative Diabetic Retinopathy (PDR) - Overview 7 Proliferative Diabetic Retinopathy (PDR) - Therapeutics under Development by Companies 8 Proliferative Diabetic Retinopathy (PDR) - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Proliferative Diabetic Retinopathy (PDR) - Products under Development by Companies 11 Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development 12 Acucela Inc. 12 Aerie Pharmaceuticals, Inc. 13 Antisense Therapeutics Limited 14 Icon Bioscience, Inc. 15 OcuCure Therapeutics, Inc. 16 Ohr Pharmaceutical Inc. 17 PanOptica, Inc. 18 Ribomic Inc. 19 ThromboGenics NV 20 Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 AR-13154 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 atesidorsen sodium - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 cyclosporine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 emixustat hydrochloride - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 OC-10X - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ocriplasmin - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 OLX-302 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 PAN-90806 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 RBM-008 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 squalamine lactate - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Proliferative Diabetic Retinopathy (PDR) - Dormant Projects 60 Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones 61 Featured News & Press Releases 61 May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 9 Comparative Analysis by Early Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Acucela Inc., H2 2016 12 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 13 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Limited, H2 2016 14 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Icon Bioscience, Inc., H2 2016 15 Proliferative Diabetic Retinopathy (PDR) - Pipeline by OcuCure Therapeutics, Inc., H2 2016 16 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ohr Pharmaceutical Inc., H2 2016 17 Proliferative Diabetic Retinopathy (PDR) - Pipeline by PanOptica, Inc., H2 2016 18 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ribomic Inc., H2 2016 19 Proliferative Diabetic Retinopathy (PDR) - Pipeline by ThromboGenics NV, H2 2016 20 Assessment by Monotherapy Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H2 2016 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.